Mostrar el registro sencillo del ítem

dc.contributor.authorBatista Ferreira, Elenilze Figueiredo
dc.contributor.authorCampos Rosa, Joaquín María 
dc.contributor.authorRodrigues dos Santos, Cleydson Breno
dc.date.accessioned2020-04-22T06:54:46Z
dc.date.available2020-04-22T06:54:46Z
dc.date.issued2019-08-14
dc.identifier.citationFerreira, E.F.B.; Silva, L.B.; Costa, G.V.; Costa, J.S.; Fujishima, M.A.T.; Leão, R.P.; Ferreira, A.L.S.; Federico, L.B.; Silva, C.H.T.P.; Rosa, J.M.C.; Macêdo, W.J.C.; Santos, C.B.R. Identification of New Inhibitors with Potential Antitumor Activity from Polypeptide Structures via Hierarchical Virtual Screening. Molecules 2019, 24, 2943. [doi:10.3390/molecules24162943]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/61454
dc.descriptionWe gratefully acknowledge the support provided by the Graduate Program in Pharmaceutical Innovation—Federal University of Amapá, Laboratory of Modeling and Computational Chemistry—Federal University of Amapá (UNIFAP-Macapá-Brazil), Computational Laboratory of Pharmaceutical Chemistry—University of Sao Paulo (USP-Ribeirão Preto-Brazil) and Department of Pharmaceutical and Organic Chemistry—Institute of Biosanitary Research ibs.GRANADA—University of Granada (UGR-Granada-Spain) for computational and financial support.es_ES
dc.description.abstractLeukemias are neoplasms that affect hematopoietic cells, which are developed by genetic alterations (mutations) that lead to the loss of proliferation control mechanisms (maturation and/or cell death). The α4β1 integrin receptor is a therapeutic target for inflammation, autoimmune diseases and lymphoid tumors. This study was carried out to search through the antagonists-based virtual screening for α4β1 receptor. Initially, seventeen (17) structures were selected (based on the inhibitory activity values, IC50) and the structure with the best value was chosen as the pivot. The pharmacophoric pattern was determined from the online PharmaGist server and resulted in a model of score value equal to 97.940 with 15 pharmacophoric characteristics that were statistically evaluated via Pearson correlations, principal component analysis (PCA) and hierarchical clustering analysis (HCA). A refined model generated four pharmacophoric hypotheses totaling 1.478 structures set of Zinc_database. After, the pharmacokinetic, toxicological and biological activity predictions were realized comparing with pivot structure that resulted in five (ZINC72088291, ZINC68842860, ZINC14365931, ZINC09588345 and ZINC91247798) structures with optimal in silico predictions. Therefore, future studies are needed to confirm antitumor potential activity of molecules selected this work with in vitro and in vivo assays.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectLeukemiaes_ES
dc.subjectα4β1 receptores_ES
dc.subjectPharmacophorees_ES
dc.subjectPCAes_ES
dc.subjectHCAes_ES
dc.titleIdentification of New Inhibitors with Potential Antitumor Activity from Polypeptide Structures via Hierarchical Virtual Screeninges_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/molecules24162943


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España